All News
High-Resolution CT in CTD-Interstitial Lung Disease
A systematic review and meta-analysis examined the role of high-resolution computed tomography (HRCT) in diagnosing and characterizing interstitial lung disease (ILD) associated with connective tissue diseases (CTDs).
Scleroderma-associated Interstitial Lung Disease
While we know there are certain clinical features serving as predictors that patients with SSc may develop ILD, including diffuse skin disease and serologies such as anti-Scl-70 and Th/To antibodies, it is imperative that clinicians consider that any patient, particularly early in their disease course (5 years of disease since the first non-Raynaud phenomenon symptom) could develop ILD.
Read Article
GLP-1 Drugs Reduce Rheumatoid Arthritis Symptoms
MedPage Today
Patients with rheumatoid arthritis (RA) who used GLP-1 receptor agonists had less disease activity and improved cardiovascular biomarkers, a small retrospective study indicated.
Read Article
Assessing ILD in Rheumatology
Janet Pope, MD, shares practical insights on how rheumatologists should assess ILD in their patients. Sponsored By: Boehringer Ingelheim
https://t.co/Mxg9P50m7C
#ILD #Rheumatology https://t.co/aAuxbJBxBn
Dr. John Cush RheumNow ( View Tweet)
Systematic review of 139 RCTs(9644 pts) & 12 Rx options for knee OA (KOA) shows simple Rx is best. For pain and function, knee brace was best, followed by exercise, and US worst. For total WOMAC best was hydrotherapy, then exercise & LaserTx. (Short wave diathermy worst) https://t.co/sN9TxJGn6N
Dr. John Cush RheumNow ( View Tweet)
🎓 Learning just got smarter.
Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates.
💡 Educational
🎯 Evidence-based
🧠 Addictive (in a good way)
Try it now and level up your clinical knowledge: https://t.co/JWTPUViFkI https://t.co/DsKunA4DkQ
Dr. John Cush RheumNow ( View Tweet)
Worsening Breathlessness in SSc ILD
Dr. Aurelie Najm, Glasgow, presents a QD Clinic on worsening breathlessness in systemic sclerosis interstitial lung disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/P3MoM7ZmIo
Dr. John Cush RheumNow ( View Tweet)
What you need to know about scleroderma-related lung fibrosis
What do you need to know about scleroderma-related lung fibrosis as a practicing rheumatologist?
https://t.co/Ezl5G5IZeI https://t.co/zTF4lIYCAJ
Dr. John Cush RheumNow ( View Tweet)
New Multidisciplinary Classification of the Interstitial Pneumonias: ATS/ERS Guideline.
https://t.co/HWteOikGXT
🫁🩻🎞⚔️🐍🧪🔬💡📚
@ERSpublications @EuroRespSoc @ALATorax @SPLF_SocPneumo @pneumosbpt @NeumoMadrid @SeparRespira @HUReinaSofia @neumoparatodos @Neumosur @NeumoNat https://t.co/GnJjuxMIEm
Links:
jpedrokessner KessnerJp ( View Tweet)
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD
When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD) is not only common in IIM, but also one of the leading causes of death, https://t.co/Kxbarq9tiD
Dr. John Cush RheumNow ( View Tweet)
🆕 ILD (Part II): advanced insights
🫁 Multidisciplinary management
💊 Treatment strategies
📊 Prognosis & monitoring
🧑⚕️ What rheums should know next
⬇️ Download & learn more: https://t.co/XNmbcfqKKF
Created by
@MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/Yhlw3nGsDh
Links:
Dr. John Cush RheumNow ( View Tweet)
Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society https://t.co/2r9oS1Eb9k https://t.co/GqKq5E0bmp
Dr. John Cush RheumNow ( View Tweet)
Study of urinary soluble CD163 levels in 214 SLE pts (129 w/ LN), found urinary CD163 highly correlates w/ UPCR, active vs inactive states, predicts Renal Bx histologic activity (AUC 0.962) & renal dz flares & allows prediction of complete, partial and non-responders https://t.co/HNKAuFDgPG
Dr. John Cush RheumNow ( View Tweet)
Controversies in ILD
This deep dive into controversies in interstitial lung disease explored complex topics including IPAF, methotrexate, systemic autoimmune rheumatic disease vs. connective tissue disease distinctions, and the evolving role of anti-fibrotic therapy. Panelists: https://t.co/ekP1Gg73yj
Dr. John Cush RheumNow ( View Tweet)
GLP-1 drugs cost-effective for knee osteoarthritis and obesity
A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee https://t.co/pqWDEUgYmI
Dr. John Cush RheumNow ( View Tweet)
🆕 Collaboration with @RheumNow 🔵
3-Part Series on #InterstitialLungDisease
Part2️⃣: Diagnosis & Subtypes of #ILD 🫁
👩🏻⚕️ What to look for on Physical Exam
🧪 Serologic Testing & Diagnostic Workup
🫁 Differentiating ILD Subtypes on Imaging
#RheumX #Pulmonology #MedTwitter #MedX https://t.co/X8cJVx2PCV
Mithu Maheswaranathan, MD MithuRheum ( View Tweet)
SARD-ILD: Significant diagnostic and treatment delays
Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease?
https://t.co/WyccifEHtY https://t.co/S6X5AhZCjz
Dr. John Cush RheumNow ( View Tweet)
KDIGO is excited to share the publication of the 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (#IgAN) and IgA Vasculitis (#IgAV), along with the Executive Summary in @Kidney_Int.
Read the Guideline in KI: https://t.co/Ygwhu3rizm
Download the Executive https://t.co/jio8N1C7KP
Links:
KDIGO goKDIGO ( View Tweet)
Join us Sept 23 @ 7PM ET for the next Rheum to Breathe Journal Club!
We’ll dive into two pivotal ILD studies:
📄 FIBRONEER (Nerandomilast in PPF) – NEJM 2025
📄 RECITAL (Rituximab vs Cyclophosphamide in CTD-ILD) – Lancet
Panelists: Dr. Toby Maher, Dr. Shervin Assassi
Moderator: https://t.co/l8EkX2hkLs
Dr. John Cush RheumNow ( View Tweet)
ILD and Mortality in Systemic Autoimmune Rheumatic Diseases
Dr. Bryant England, Lincoln, NE, discusses interstitial lung disease and mortality in systemic autoimmune rheumatic diseases (SARDs), as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month https://t.co/wtg9Te6oth
Dr. John Cush RheumNow ( View Tweet)
